While longitudinal studies on the impact of alemtuzumab on peripheral and CNS B cells are difficult to perform in MS patients themselves, the EAE model offers the possibility of investigating long-term effects of anti-CD52 antibody treatment on both the autoimmune response and also on neurodegeneration and nueroregeneration. The gene discussed is CD52; the disease is myeloid sarcoma.